Skip to main content

Table 5 Chemical neuroimaging findings in panic disorder [magnetic resonance spectroscopy]

From: The role of the amygdala in the pathophysiology of panic disorder: evidence from neuroimaging studies

Study

Subjects

No. of subjects (female)

Mean age (SD)

Clinical state

Comorbid Depression

Comorbid Agora-phobia

Medication status

Field strength (Tesla)

Imaging method

Study paradigm

Amygdala

Hippocampus

Ventromedial Prefrontal cortex

Other brain regions

Induced Panic Attack

Friedman, 2006 [29]

PD

9 (4)

42.7 (15.3)

API 7.39 (7.19) Anxiety ratings 1.56 (1.33) Panic ratings 2.33 (1.94)

None

 

Fluoxetine, n = 8; Gabapentin, n = 1

1.5

31P-MRS

Regulated hyperventilation

   

Blunted pH response in PD

HC

11 (8)

31.5 (9.6)

API 1.63 (2.06) Anxiety ratings 0.09 (0.30) Panic ratings 0 (0)

   

Layton, 2001 [30]

PD

6 (3)

 

API 20.3 (5.2) Panic severity 6.7 (2.4) Anxiety severity 2.8 (1.5)

   

1.5

PEPSI

Panic induced by initial intravenous sodium lactate infusion/second infusion with gabapentin responders, n = 4; placebo responders, n = 2

   

No significant difference in Lactate/NAA levels between conditions (although gabapentin reduced clinical response to infusion)

Dager, 1999 [31]

PD

15 (8)

33.1 (11.7)

API 8.9 (8.2) Panic Severity 2.4 (3.0) Anxiety Severity 2.1 (1.3)

None

 

Free for 1 month

1.5

PEPSI

Panic induced by intravenous sodium lactate infusion (Panickers, n = 12)

   

Panickers: Earlier global Lactate/NAAâ–²

HC

10 (6)

32.7 (7.4)

API 1.5 (1.8) Panic Severity 0.2 (0.4) Anxiety Severity 0.5 (0.9)

   

Dager, 1997 [32]

PD

13 (8)

36.2 (9.1)

API 25.7 (9.7) Panic Severity 8.0 (1.9)

None

 

Free for 1 month

1.5

1 H-MRS

Panic induced by intravenous sodium lactate infusion (Panickers, n = 10)

   

PD patients: Insular cortex Lactate/NAAâ–²

HC

10 (6)

37.7 (7.5)

API 4.5 (2.5)

   

Dager, 1994 [33]

PD

8 (4)

38.6 (7.2)

 

None

 

Fluoxetine, n = 3; Fluoxetine + alprazolam, n = 1; Imipramine, n = 1

1.5

1 H-MRS

Panic induced by intravenous sodium lactate infusion

(Panickers, n = 3)

   

Panickers: Insular cortex Lactate/NAAâ–²

HC

8 (2)

36.0 (6.8)

   

Others

Trzesniak, 2010 [34]

PD

25 (19)

39.2 (9.9)

 

History, n = 13

Current, n = 10

SSRI, n = 8 Clorimipramine, n = 2 BZD, n = 3 BZD + SSRI, n = 3

1.5

1 H-MRS

-

 

Left hippocampus NAA/Crâ–¼

  

HC

      

Hasler, 2009 [35]

PD

17 (12)

34.2 (10.1)

PD onset 22 (8.9) yrs PD duration 21 (31) mts PDSS 7.5 (3.0); PSS 18 (5.4) HAM-A 9.6 (6.2) HAM-D 9.6 (7.4)

Current MDD, n = 7

Current, n = 7

Medication naive, n = 9; Free for 3 months, n = 8

3.0

1 H-MRS

-

  

No significant difference GABA, Glx, CHO, NAA

No significant difference in DM/DALPFC GABA, Glx, CHO, NAA

HC

17 (12)

35.1 (11.8)

    

Maddock, 2009 [36]

PD

15 (10)

37.5 (9.2)

STAI-S 41.3 (10.6) API 2.1 (2.7) PAS 22.7 (10.5) ASI 36.9 (14)

Past MDD, n = 1

Current, n = 14

Untreated, n = 15

1.5

1 H-MRS

Vigilance task with visual stimuli

   

Visual cortex Lactate/NAAâ–²

HC

15 (10)

37.1 (6.9)

STAI-S 25.4 (9.8) API 0.3 (1.0)

   

Ham, 2007 [37]

PD

24 (10)

31.9 (6.8)

PDSS 9.5 (6.4) HAM-D 4.7 (5.0)

Not current

 

Combination of antidepressants and anxiolytics

3.0

1 H-MRS

   

GABAâ–¼ Lactateâ–² Choâ–²

Basal ganglia GABAâ–¼

HC

24 (10)

30.5 (5.2)

HAM-D 5.2 (4.1)

   

Goddard, 2004 [38]

PD

10 (5)

36 (11)

 

None

With/Without

Medication naive, n = 5; Free for 3 months, n = 2; BDZ until 1 week before, n = 3

2.1

1 H-MRS

Acute oral, open-label BDZ (clonazepam) administration

   

Occipital cortex GABAâ–¼

HC

10 (5)

31.5 (9.6)

    

Massana, 2002 [39]

PD

11 (6)

34.27 (6.92)

 

None

All with some degree

All were antidepressant-naive and medication-free for 2 weeks

1.5

1 H-MRS

-

  

No significant difference in medial frontal cortex

Right medial temporal lobe Cr + PCr▼ ;

 

HC

11 (6)

34.55 (6.95)

           

Goddard, 2001 [40]

PD

14 (8)

37 (10)

PDSS 13 (4), n = 13HAM-A 17 (8) 25-item HAM-D 20 (10) 17-item HAM-D 14 (6)CRAS 31 (16)

None

With/Without

Medication naive, n = 9; Free for 3 months, n = 2; BDZ until 1 week before, n = 3

2.1

1 H-MRS

-

   

Occipital cortex GABAâ–¼ , significant in Female Panickers

HC

14 (8)

31.5 (9.6)

    

Shioiri, 1996 [41]

PD

18 (10)

35.9 (9.1)

HAM-A 9.8 (6.3)

None

 

All on BDZ

1.5

31P-MRS

-

   

Frontal lobe slight Pi▼ ; Frontal lobe PCr L > R asymmetry

HC

18 (10)

35.3 (11.4)

    
  1. Abbreviations: API, Acute Panic Inventory; ASI, Anxiety Sensitivity Index; BDZ, benzodiazepine; Cho, choline; Cr, creatine; CRAS, Clinician-Rated Anxiety Scale; DM/DALPFC, dorsomedial/dorsal anteromedial prefrontal cortex; GABA, gamma-aminobutyric acid; Glx, glutamte + glutamine; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HC, healthy control; NAA, N-acetyl aspartate; PAS, Panic and Agoraphobia Scale; PCr, phosphocreatine; PD, panic disorder; PDSS, Panic Disorder Severity scale; PEPSI, proton echo-planar spectroscopic imaging; Pi, inorganic phosphate; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor; STAI-S, State Trait Anxiety Index-State version.